Clinical trial
A Phase 1, Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Hepatic Function
NCT02412098 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Hepatic Function
- Lead sponsor
- Gilead Sciences
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 19, 2015
- Completion date
- April 22, 2016
- Enrollment
- 49 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.